Morinda citrifolia as a 5-Lipoxygenase inhibitor

1-16. (canceled)

17. A method for inhibiting Lipoxygenase and for treating and preventing inflammatory diseases within a mammal, said method comprising the steps of:

adding a processed Morinda citrifolia product to an alcohol-based solution;

isolating and extracting an active ingredient of said processed Morinda citrifolia product from said solution to obtain a fraction;

introducing said extracted active ingredient into said mammal, wherein said extracted active ingredient inhibits, prevents, reduces, and reverses the effects of inflammatory diseases.

18. The method of claim 17, wherein said processed Morinda citrifolia product comprises processed Morinda citrifolia fruit juice.

19. The method of claim 17, wherein said processed Morinda citrifolia product comprises processed Morinda citrifolia puree.

20. The method of claim 17, wherein said alcohol-based solution is selected from the group consisting essentially of methanol, ethanol, and ethyl acetate, and other alcohol-based derivatives.

21. The method of claim 17, wherein said active ingredient is Quercetin.

22. The method of claim 21, wherein said active ingredient is Rutin that synergistically works with said Quercetin to inhibit said Lipoxygenase.

23. The method of claim 17, wherein said active ingredient is a soluble alcohol supernate fraction.

24. The method of claim 17, wherein said step of introducing said extracted active ingredient comprises orally administering two ounces of a food product to a patient twice daily each day on an empty stomach, said food product comprising said active ingredient obtained from said processed Morinda citrifolia product.

25. The method of claim 17, wherein said step of introducing said extracted active ingredient comprises applying a topical composition to said area, said topical composition comprising said active ingredient obtained from said processed Morinda citrifolia product.

26. A method for inhibiting Lipoxygenase and treating and preventing inflammatory diseases and the symptoms associated therewith within a mammal, said method comprising the steps of:

orally administering to said mammal at least one ounce of a naturaceutical formulation comprising a processed Morinda citrifolia product on an empty stomach in the morning;

orally administering to said mammal at least one ounce of said naturaceutical formulation on an empty stomach prior to sleeping at night; and

repeating said steps of orally administering each day until said estrogen-dependent cancerous cells are destroyed.

27. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia fruit juice present in an amount by weight of about 100 percent.

28. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia fruit juice present in an amount by weight between about 85-99.99 percent; and

water present in an amount by weight between about 0.1-15 percent.

29. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia fruit juice present in an amount by weight between about 85-99.99 percent; and

non-Morinda citrifolia-based fruit juices present in an amount by weight between about 0.1-15 percent.

30. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia fruit juice present in an amount by weight between about 50-90 percent;

water present in an amount by weight between about 0.1-50 percent; and

non-Morinda citrifolia-based fruit juices present in an amount between about 0. 1-30 percent.

31. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia puree juice present in an amount by weight of about 100 percent.

32. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia puree juice present in an amount by weight between about 85-99.99 percent; and

water present in an amount by weight between about 0.1-15 percent.

33. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia puree juice present in an amount by weight between about 85-99.99 percent; and

non-Morinda citrifolia-based fruit juices present in an amount by weight between about 0.1-15 percent.

34. The method of claim 26, wherein said naturaceutical formulation comprises:

processed Morinda citrifolia puree juice present in an amount by weight between about 50-90 percent;

water present in an amount by weight between about 0.1-50 percent; and

non-Morinda citrifolia-based fruit juices present in an amount between about 0. 1-30 percent.

35. The method of claim 26, wherein said step of orally administering comprises orally administering two ounces of said naturaceutical formulation.

36-62. (canceled)